Displaying 2581 - 2600 of 4553
FTC Requests Public Comment on Community Health Systems’ Application to Approve Sale of Carolina Pines Regional Medical Center to Capella Healthcare, Inc.
FTC Approves SCI’s Applications to Divest Assets in California, Florida, and Tennessee
Federal Trade Commission Appoints Ashkan Soltani as Chief Technologist
FTC Approves Final Order Preserving Competition in the Market for Over-the-Counter Motion Sickness Drugs
Prestige Brands Holdings, Inc. and Insight Pharmaceuticals Corporation, In the Matter of
Pharmaceutical company Prestige Brands Holdings, Inc., the maker of Dramamine, agreed to divest assets and marketing rights for the over-the-counter motion sickness drug Bonine to settle FTC charges that Prestige’s proposed acquisition of Insight Pharmaceuticals Corporation would likely be anticompetitive. Prestige proposed to acquire Insight for $750 million. According to the FTC’s complaint, Prestige’s Dramamine, which is the best-selling branded product in the market for over-the-counter motion-sickness drugs, and Insight’s Bonine, are the only two branded products with significant sales. Absent a remedy, the acquisition would eliminate the close competition between Dramamine and Bonine, likely leading to higher prices for consumers.
FTC Approves Final Orders Requiring Two Professional Associations to Eliminate Rules that Restrict Competition among Their Members
National Association of Teachers of Singing, Inc., In the Matter of
The National Association of Teachers of Singing, Inc. (NATS) has agreed to eliminate provisions in its code of ethics that limit competition among its members. The FTC charged that NATS, which represents more than 7,300 vocal arts teachers in the United States, restrained competition in violation of the FTC Act through a code of ethics provision that prohibits members from soliciting students from other members. The order settling the FTC’s complaint against NATS requires that it stop restraining members from seeking teaching work, and stop telling its members that soliciting students is unethical. The order also requires NATS to obtain a certification from each of its chapters that the chapter is not restricting solicitation, advertising, or price-related competition by its members, and to sever its ties with any chapter that NATS learns is restraining solicitation, advertising, or price-related competition by its members. NATS also must implement an antitrust compliance program.
National Association of Residential Property Managers, Inc., In the Matter of
The National Association of Residential Property Managers, Inc. (NARPM) has agreed to eliminate provisions in its code of ethics that limit competition among its members. The FTC’s complaint against NARPM, which represent more than 4,000 real estate managers, brokers, and agents, alleges that NARPM and its members restrained competition in violation of the FTC Act through provisions in its code of ethics that restrict comparative advertising and solicitation of competitor’s clients. The proposed consent order settling the FTC’s charges requires NARPM to stop restraining its members from soliciting property management work, and from making statements that are not false or deceptive about a competitor’s products, services, or business or commercial practices. NARPM also must implement an antitrust compliance program.
FTC Staff Comment Before the Texas State Board of Dental Examiners Concerning Proposed 22 TEX ADMIN CODE §§ 108.70, 108.74 That Would Restrict the Ability of Texas Dentists to Enter into Agreements with Non-Dentists for the Provision of Admin Services
FTC Staff Comment: Proposed Dental Services Rules in Texas Would Likely Reduce the Benefits of Competition for Consumers
FTC Approves Modified Consent Order for Graco Inc.
Interview with FTC Commissioner Maureen Ohlhausen on C-SPAN’s “The Communicators”
Advertising Allowances and Other Merchandising Payments and Services ("Fred Meyer Guides")
FTC Approves Final Amendments to Guides to Help Businesses Comply with Law Regarding Promotional Allowances and Services
FTC Approves Final Order Preserving Future Competition in Generic Injectable Tuberculosis Drug Market
FTC Approves Four SCI Applications to Divest Funeral and Cemetery Assets in Georgia and Tennessee
Akorn, Inc., In the Matter of
Akorn, Inc. has agreed to sell its rights to develop, manufacture, and market the generic injectable tuberculosis drug, rifampin, in order to settle FTC charges that Akorn’s proposed acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would likely be anticompetitive. According to the FTC’s complaint, only VersaPharm and two other firms currently have FDA approval to sell generic injectable rifampin and there are no viable substitutes for rifampin as a course of treatment for tuberculosis. The FTC’s proposed settlement with Akorn requires the company to divest its Abbreviated New Drug Application for generic injectable rifampin – which is currently pending before the Food and Drug Administration – to Watson Laboratories, Inc.
Displaying 2581 - 2600 of 4553